1310P - Prognostic Impact of Serum Cyfra 21-1 In Advanced Lung Adenocarcinoma

Abstract

ABSTRACT Background Serum CYFRA 21-1 is one of the most important serum markers in diagnosing non-small cell lung cancer (NSCLC), especially squamous-cell carcinoma. It is not known whether pretreatment serum CYFRA 21-1 values (PCV) have prognostic implications in advanced lung adenocarcinoma. The aim of this study was to evaluate the prognostic implications of PCV in advanced lung adenocarcinoma. Material and methods Out of 424 newly diagnosed lung cancer patients (pts) at our institution during the period April 2008- June 2010, we retrospectively reviewed 284 consecutive pts who were diagnosed with advanced lung adenocarcinoma and had been treated with systemic chemotherapy. Survival was estimated using the Kaplan-Meier method. A log-rank test was performed to test the significance of differences in the overall survival among the groups. A multivariate analysis using the Cox proportional hazards model was used to establish the association between various prognostic factors and survival. Results One hundred twenty one pts (43%) had activating EGFR mutations (Mt+) and 163 pts (57%) had EGFR wild type (Mt-). The median follow-up time was 29.7 months (range: 2.8- 75.7 months). In univariate analysis, gender (male/ female), ECOG performance status (PS) (0-2/ 3-4), PCV ( 2.2ng/ml), EGFR mutation (Mt + / Mt-), and smoking history (yes/ no) were favorable prognostic factors (p= 0.01, p 70], p = 0.67). A Cox's multivariate analysis showed that PCV ( 2.2ng/ml (n= 48) (median survival time [MST]: 52.4 vs. 21.0 months, p 2.2ng/ml (n = 86) (MST: 24.1 vs. 10.2 months, p Conclusions PCV should be regarded as a potential independent prognostic factor in both Mt+ and Mt- advanced lung adenocarcinoma. Disclosure All authors have declared no conflicts of interest.